Back to Search Start Over

Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy

Authors :
Chun-Nung Huang
Yeong-Shiau Pu
Chia-Chu Liu
Tony T. Wu
Victor C. Lin
Chao-Yuan Huang
Shu-Pin Huang
Jyh-Seng Wang
Chun-Hsiung Huang
Chia-Cheng Yu
Bo-Ying Bao
Source :
Annals of Surgical Oncology. 20:492-499
Publication Year :
2013
Publisher :
Springer Science and Business Media LLC, 2013.

Abstract

Cyclin D1 (CCND1) is an important cell-cycle regulator involved in carcinogenesis and progression of prostate cancer. We tested whether genetic variations within the CCND1 gene are related to clinical outcomes in prostate cancer patients receiving radical prostatectomy.A total of 320 clinical localized prostate cancer patients who underwent radical prostatectomy in Taiwan were prospectively follow-up in this study. A total of 5 tagged single-nucleotide polymorphisms that captured the genetic variability across the CCND1 gene were genotyped, and the prognostic significance on prostate-specific antigen (PSA) recurrence was assessed using the Kaplan-Meier analysis and Cox regression model.We found a polymorphism, rs9344, and 2 haplotypes, GAGG and CTGG, consisting of rs667515, rs2450254, rs9344, and rs678653, were associated with PSA recurrence (P ≤ 0.033). After adjusting for other clinicopathologic predictors, including age, PSA levels, pathologic stage, Gleason score, and surgical margin, rs9344 and the haplotype CTGG remained significant (P ≤ 0.044). The model based on clinical variables plus CCND1 rs9344 or haplotype showed improvement over the model without genetic information, as indicated by ≥ 7.2 % net reclassification improvement (P ≤ 0.040), integrated discrimination index (P ≤ 0.041), and likelihood ratio test (P ≤ 0.028).Our data suggest that the CCND1 rs9344 and a specific haplotype CTGG may be prognostic factors for PSA recurrence after radical prostatectomy.

Details

ISSN :
15344681 and 10689265
Volume :
20
Database :
OpenAIRE
Journal :
Annals of Surgical Oncology
Accession number :
edsair.doi.dedup.....dc526e41fac8ce90c20dd96650efbbbc